NCT04309175Unknown不适用
Effect of Long-term Atrial Pacing on Central Blood Pressure in Permanently Paced Sick Sinus Syndrome Patients With Primary Arterial Hypertension
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 58
- 主要终点
- systolic blood pressure amplification change
研究概览
简要总结
This is a randomized controlled single-centre clinical trial with a cross-over design to compare non-invasively evaluated central blood pressure and related parametres in sick sinus syndrome patients with hypertension who are paced long-term at a slower vs faster heart rate
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •age 18-80 years
- •sick sinus syndrome
- •permanent cardiac pacemaker with right atrial and right ventricular leads
- •at least 3 months from implantation
- •sinus rhythm
- •percentage of atrial pacing at or above 80% since last interrogation
- •percentage of ventricular pacing at or below 3% since last interrogation
- •primary arterial hypertension
- •antihypertensive drug treatment
- •mean office brachial blood pressure below 140/90 mmHg
- •mean home brachial blood pressure below 135/85 mmHg
- •ability to understand and follow study protocol
- •signed informed consent form
排除标准
- •inclusion criteria not fulfilled
- •violation of study protocol by subject, investigator or third part
- •high quality central hemodynamic measurements cannot be perfomed
- •inter-arm difference in brachial systolic blood pressure 15 mmHg or above
- •intrinsic QRS complex 130 ms or above
- •more than three antihypertensive agents in use
- •treatment with digoxin or agents from Vaughan-Williams classes Ic, III või IV
- •frequent high atrial rate episodes
- •coronary artery disease
- •secondary hypertension
- •resistant hypertension
- •orthostatic hypotension
- •heart failure with decreased or preserved left ventricular ejection fraction
- •implantable cardioverter-defibrillator or cardiac resynchronization therapy
- •significant valvular heart disease
- •significant congenital heart disease
- •body mass index ≥35 kg/m2
- •type I diabetes
- •type II diabetes with cardiovascular complications or on insulin therapy
- •other significant endocrine disease
- •history of cerebrovascular attack
- •carotid artery disease
- •lower extremity arterial disease
- •severe chronic obstructive pulmonary disease
- •severe asthma
- •severe sleep apnea
- •interstitial pulmonary disease
- •inhaled beta adrenergic agonist therapy
- •active cancer treatment
- •central nervous system degenerative disease
- •systemic connective tissue disease
- •abnormal TSH at present
- •glomerular filtration rate ≤30 ml/min/m2
- •hemoglobin <100 g/L (female), <110 g/L (male)
- •hepatic dysfunction
- •alcohol abuse
- •pregnancy or breastfeeding
- •no health insurance provided by Estonian Health Insurance Fund
- •withdrawal of informed consent
- •loss of contact with a subject during study
结局指标
主要结局
systolic blood pressure amplification change
时间窗: two months
次要结局
未报告次要终点
研究者
Tuuli Teeäär
cardiologist
Tartu University Hospital
相似试验
招募中
不适用
Evaluation of PWI Assisted by Marshall Ethanolization in Ablation of Persistent Atrial FibrillationAtrial FibrillationNCT06363604Xinhua Hospital, Shanghai Jiao Tong University School of Medicine260
招募中
不适用
SCAR Burden of Left Atrium Guided cathEter Ablation sTrategy for Persistent Atrial FibrillationAtrial FibrillationNCT05794386Seoul National University Hospital204
已完成
不适用
SAFE Study - Septal Pacing for Atrial Fibrillation Suppression EvaluationAtrial FibrillationNCT00419640Abbott Medical Devices385
已完成
不适用
Impact of Catheter Ablation on ABC Risk ScoresBleedingAtrial RemodelingRecurrencesStrokeAtrial FibrillationAtrial FlutterNCT05635864Hannover Medical School167
已完成
不适用
Evaluation of VDD Leadless Pacing System During ExerciseBradycardiaPacemaker DDDNCT06094114Universitaire Ziekenhuizen KU Leuven42